Department of Urology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.
Samaritan Biologics, Cordova, TN, USA.
BMC Urol. 2024 Sep 28;24(1):208. doi: 10.1186/s12894-024-01593-7.
Localized prostate cancer (PCa) is one of the most common malignancies in the United States. Despite continued refinement of robot assisted radical prostatectomy (RARP) surgical methods, post-surgical erectile dysfunction and urinary incontinence remain significant challenges due to iatrogenic injury of local nervous tissue. Thus, the development of therapeutic strategies, including the use of biologic adjuncts to protect and/or enhance recovery and function of nerves following RARP is of growing interest. Perinatal tissue allografts have been investigated as one such biologic adjunct to nerve sparing RARP. However, knowledge regarding their clinical efficacy in hastening return of potency and continence as well as the potential underpinning biological mechanisms involved remains understudied. Thus, the objective of this literature review was to summarize published basic science and clinical studies supporting and evaluating the use of perinatal allografts for nerve repair and their clinical efficacy as adjuncts to RARP, respectively.
The literature as of May 2024 was reviewed non-systematically using PubMed, EMBASE, Scopus, and Web of Science databases. The search terms utilized were "robotic prostatectomy", "prostate cancer", "nerve sparing", "perinatal tissue", "allograft", "potency", and "continence" alone or in combination. All articles were reviewed and judged for scientific merit by authors RP and JM, only peer-reviewed studies were considered.
Eight studies of perinatal tissue allograph use in RARP were deemed worthy of inclusion in this nonsystematic review.
Incontinence and impotence remain significant comorbidities despite continued advancement in surgical technique. However, basic science research has demonstrated potential neurotrophic, anti-fibrotic, and anti-inflammatory properties of perinatal tissue allografts, and clinical studies have shown that patients who receive an intra-operative prostatic perinatal membrane wrap have faster return to potency and continence.
局部前列腺癌(PCa)是美国最常见的恶性肿瘤之一。尽管机器人辅助根治性前列腺切除术(RARP)手术方法不断改进,但由于局部神经组织的医源性损伤,术后勃起功能障碍和尿失禁仍然是一个重大挑战。因此,开发治疗策略,包括使用生物辅助物来保护和/或增强 RARP 后神经的恢复和功能,越来越受到关注。围产期组织同种异体移植物已被研究作为一种神经保护 RARP 的生物辅助物。然而,关于它们在加速恢复勃起功能和尿失禁方面的临床疗效以及所涉及的潜在潜在生物学机制的知识仍然研究不足。因此,本文献综述的目的是总结支持使用围产期同种异体移植物进行神经修复的已发表的基础科学和临床研究,并分别评估它们作为 RARP 辅助物的临床疗效。
截至 2024 年 5 月,使用 PubMed、EMBASE、Scopus 和 Web of Science 数据库进行了非系统性文献回顾。使用的检索词是“机器人前列腺切除术”、“前列腺癌”、“神经保护”、“围产期组织”、“同种异体移植物”、“勃起功能”和“尿失禁”单独或组合使用。作者 RP 和 JM 对所有文章进行了回顾和科学价值判断,仅考虑了同行评议的研究。
有 8 项关于围产期组织同种异体移植物在 RARP 中的应用的研究被认为值得纳入本非系统性综述。
尽管手术技术不断进步,但尿失禁和勃起功能障碍仍然是严重的合并症。然而,基础科学研究已经证明了围产期组织同种异体移植物具有潜在的神经营养、抗纤维化和抗炎特性,临床研究表明,接受术中前列腺围产期膜包裹的患者更快地恢复勃起功能和尿失禁。